Cargando…
Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease
“Mutational signatures” are patterns of mutations that report DNA damage and subsequent repair processes that have occurred. Whole-genome sequencing (WGS) can provide additional information to standard diagnostic techniques and can identify therapeutic targets. A 32-yr-old male with xeroderma pigmen...
Autores principales: | Momen, Sophie, Fassihi, Hiva, Davies, Helen R., Nikolaou, Christos, Degasperi, Andrea, Stefanato, Catherine M., Dias, Joao M. L., Dasgupta, Dhruba, Craythorne, Emma, Sarkany, Robert, Papa, Sophie, Nik-Zainal, Serena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824248/ https://www.ncbi.nlm.nih.gov/pubmed/31645345 http://dx.doi.org/10.1101/mcs.a004408 |
Ejemplares similares
-
Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers
por: Fernandez, Elvelyn R., et al.
Publicado: (2023) -
Xeroderma pigmentosum is a definite cause of Huntington's disease‐like syndrome
por: Garcia‐Moreno, Hector, et al.
Publicado: (2017) -
Angiosarcoma of the scalp associated with Xeroderma pigmentosum
por: Sharma, Shilpi, et al.
Publicado: (2012) -
Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression
por: Garcia-Moreno, Hector, et al.
Publicado: (2023) -
Angiosarcoma of the Auricle in a Patient with Xeroderma Pigmentosum Variant
por: Onishi, Masazumi, et al.
Publicado: (2020)